Skip to main content
. Author manuscript; available in PMC: 2021 Oct 15.
Published in final edited form as: Cancer Res. 2021 Feb 15;81(8):1965–1976. doi: 10.1158/0008-5472.CAN-20-3213

Figure 1. Tet2-deficient TILs exhibit enhanced anti-tumor activity in vivo.

Figure 1.

A. Experimental design of adoptive transferring in vitro-generated OT-I CD8+ T cells (WT and Tet2KO; CD45.2+) into recipient mice (CD45.1+) bearing subcutaneous B16-OVA tumors. The mice were then treated with or without an anti-PD-L1 antibody at 3 and 6 days after T cell transfer.

B. Quantification of B16-OVA melanoma tumor size in four experimental groups: WT control (CTL; black), WT with anti-PD-L1 treatment (green), Tet2KO (red), Tet2KO with anti-PD-L1 treatment (blue). Data were shown as mean ± S.D; n=16–27 mice; P values were listed on the right next to the curves (two-tailed Student’s t-test).

C. Quantification of the percentage of CD45.2+CD8+ TILs (WT vs Tet2KO) in CD8+ T cells population with and without anti-PD-L1 treatment at 8 days after adoptive transfer. Data were shown as mean ± S.D; n=12–24 mice, ** P < 0.005 (two-tailed Student’s t-test).

D. Comparison of the relative distribution of adoptively transferred WT (black) and Tet2KO (red) CD45.2+CD8+ cells in tumor (TILs), spleen (SPL) and peripheral blood (PB) at 8 days in the recipient mice. The data were shown as the fold change relative to WT in TILs, spleen and peripheral blood. Data were shown as mean ± S.D; n=6–11 mice, * p < 0.05, by two-tailed Student’s t-test.

E. Percentage of adoptively transferred WT (left) and Tet2KO (right) CD45.2+CD8+ T cells within tumor (TILs), spleen (SPL) and peripheral blood (PB) at 8 days after adoptive transfer. Data were shown as mean ± S.D; n=6–11 mice.